Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma

[1]  K. Wester,et al.  Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer , 2012, Proteomics.

[2]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[3]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[4]  M. Zeegers,et al.  Assessment of high‐throughput high‐resolution MALDI‐TOF‐MS of urinary peptides for the detection of muscle‐invasive bladder cancer , 2011, Proteomics. Clinical applications.

[5]  H. Grossman,et al.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[6]  Wen‐Cheng Chen,et al.  Characterization of ADAM28 as a biomarker of bladder transitional cell carcinomas by urinary proteome analysis. , 2011, Biochemical and biophysical research communications.

[7]  Ying Liang,et al.  Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. , 2011, Journal of proteome research.

[8]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[9]  Sanjeeva Srivastava,et al.  Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.

[10]  T. Hwang,et al.  Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer Detection , 2011, PloS one.

[11]  Yu-Sun Chang,et al.  Importin subunit alpha‐2 is identified as a potential biomarker for non‐small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome , 2011, International journal of cancer.

[12]  K. Shedden,et al.  Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification , 2011, Clinical Cancer Research.

[13]  M. Mann,et al.  Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. , 2011, Journal of proteome research.

[14]  Chia-Wei Hsu,et al.  Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. , 2010, Journal of proteome research.

[15]  Li‐yu Lee,et al.  Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis , 2010, Proteomics.

[16]  A. Vlahou,et al.  Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. , 2010, Journal of proteome research.

[17]  M. Zeegers,et al.  The West Midlands Bladder Cancer Prognosis Programme: rationale and design , 2010, BJU international.

[18]  N. Anderson,et al.  The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.

[19]  Yusuke Nakamura,et al.  Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. , 2009, International journal of oncology.

[20]  Yair Lotan,et al.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. , 2009, European urology.

[21]  M. Burset,et al.  DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. , 2009, The Journal of urology.

[22]  Ton G van Leeuwen,et al.  A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. , 2009, European urology.

[23]  A. Hongo,et al.  The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. , 2009, International journal of oncology.

[24]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[25]  G. Tsujimoto,et al.  Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer , 2008, Clinical Cancer Research.

[26]  F. Algaba,et al.  Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. , 2007, Journal of proteome research.

[27]  W. Jiang,et al.  Hepatocyte growth factor activation inhibitors (HAI‐1 and HAI‐2) regulate HGF‐induced invasion of human breast cancer cells , 2006, International journal of cancer.

[28]  H. Fuse,et al.  Serum hepatocyte growth factor activator inhibitor type I (HAI‐I) and type 2 (HAI‐2) in prostate cancer , 2006, The Prostate.

[29]  A. Steinle,et al.  Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.

[30]  Troels Z. Kristiansen,et al.  Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.

[31]  H. Huland,et al.  Stage‐dependent increase of orosomucoid and zinc‐alpha2‐glycoprotein in urinary bladder cancer , 2005, Proteomics.

[32]  S. Shariat,et al.  Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. , 2005, European urology.

[33]  W. Schmiegel,et al.  Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer , 2005, Proteomics.

[34]  Mogens Kruhøffer,et al.  Gene Expression in the Urinary Bladder , 2004, Cancer Research.

[35]  T. Isono,et al.  Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. , 2004, Clinical chemistry.

[36]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[37]  H. Miyake,et al.  Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  K. Ashida,et al.  High levels of urinary midkine in various cancer patients. , 2003, Biochemical and biophysical research communications.

[39]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[40]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[41]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[42]  W. Jiang,et al.  Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. , 2001, International journal of oncology.

[43]  H. Tanaka,et al.  A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers. , 2001, Biochemical and biophysical research communications.

[44]  K. Miyazawa,et al.  Hepatocyte Growth Factor Activator Inhibitor Type 1 Is a Specific Cell Surface Binding Protein of Hepatocyte Growth Factor Activator (HGFA) and Regulates HGFA Activity in the Pericellular Microenvironment* , 2000, The Journal of Biological Chemistry.

[45]  M. Sánchez-Carbayo,et al.  Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. , 1999, Urology.

[46]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[47]  G. Kimura,et al.  Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. , 1996, Urology.

[48]  A. Harris,et al.  The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. , 1996, Cancer research.

[49]  L. Kivisaari,et al.  CT in determining the depth of infiltration of bladder tumors , 1985, Urologic radiology.